BioCentury
ARTICLE | Clinical News

Tivantinib: Additional Phase II data

May 28, 2012 7:00 AM UTC

Additional data from a double-blind, international Phase II trial in 107 patients with unresectable HCC who failed 1 prior systemic therapy showed that twice-daily oral tivantinib missed the secondary endpoint of median PFS vs. placebo (1.7 vs. 1.5 months, p=0.06). In a subgroup of 37 patients whose tumors had high c-Met expression, tivantinib led to a median TTP and PFS of 2.9 and 2.4 months, respectively, vs. 1.5 and 1.5 months for placebo (p=0.03 and p=0.02). Data will be presented at the American Society of Clinical Oncology meeting in Chicago in June. ...